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PSAa b s t r a c t
Purpose: The effectiveness of stereotactic body radiotherapy (SBRT) for localized prostate cancer is tested.
Methods and materials: A total of 1100 patients with clinically localized prostate cancer were enrolled in
separate prospective phase 2 clinical trials of SBRT from 8 institutions during 2003–11 and pooled for
analysis. SBRT using the CyberKnife delivered a median dose of 36.25 Gy in 4–5 fractions. Patients were
low-risk (58%), intermediate-risk (30%) and high-risk (11%). A short-course of androgen deprivation ther-
apy (ADT) was given to 14%. PSA relapse deﬁned as a rise >2 ng/ml above nadir was analyzed with the
Kaplan Meier method.
Results: With a median follow-up of 36 months there were 49 patients with PSA failure (4.5%), 9 of whom
were subsequently determined to be benign PSA bounces. The 5-year biochemical relapse free survival
(bRFS) rate was 93% for all patients; 95%, 83% and 78% for GS 66, 7 and P8, respectively (p = 0.001),
and 95%, 84% and 81% for low-, intermediate- and high-risk patients, respectively (p < 0.001). No differ-
ences were observed with ADT (p = 0.71) or as a function of total dose (p = 0.17). A PSA bounce of >0.2 ng/
ml was noted among 16% of patients. For 135 patients possessing a minimum of 5 years follow-up, the 5-
year bRFS rate for low- and intermediate-risk patients was 99% and 93%, respectively.
Conclusion: PSA relapse-free survival rates after SBRT compare favorably with other deﬁnitive treatments
for low and intermediate risk patients. The current evidence supports consideration of SBRT among the
therapeutic options for these patients.
 2013 The Authors. Published by Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology
109 (2013) 217–221The long term effectiveness and safety of hypofractionated
external beam radiotherapy in the deﬁnitive treatment of prostate
cancer was ﬁrst suggested by a landmark program which ran in the
UK during the 1980s that delivered 6 fractions of 6 Gy each over a
two week period [1]. Over the ensuing two decades the evolution
of radiotherapy technology to integrate 3D anatomy, conformal
dose coverage and image guidance combined with a deeper under-
standing of the radiobiology of prostate cancer led to the prolifer-
ation of various fractionated radiotherapy schedules.Consequently, substantial clinical data now exist from several
studies including randomized trials using various moderately hyp-
ofractionated regimens, with dose-per-fraction ranging from
2.5 Gy per fraction to 70 and 3.1 Gy per fraction to 62 Gy [2–10]
and more recently, extreme hypofractionation schemes of
7.25 Gy per fraction for 36.25–10 Gy for 50 Gy [11–18] using ste-
reotactic body radiotherapy (SBRT) approaches.
The basis for the successful clinical results from these hypofrac-
tionation schemes stems from the unique radiobiology of prostate
cancer that favors large dose per fraction over conventionally frac-
tionated schedules. Indeed, a recent systematic review and analy-
sis [19] combining the clinical outcomes after various
hypofractionated schedules for prostate cancer involving over
2800 patients compared to conventionally fractionated regimens
among over 11,000 patients conﬁrmed that prostate cancer has a
very high sensitivity to dose per fraction (i.e., quantiﬁed by the lin-
ear quadratic radiobiologic relationship as a low a/b ratio of 1.0–
1.7). Consequently, hypofractionation for prostate results in a
218 Stereotactic body radiotherapy for localized prostate cancermeans of radiobiological dose-escalation and probably represents a
therapeutic gain. It also affords a more economical course of deﬁn-
itive radiotherapy, improves patient access to care, and enhances
patient convenience.
In 2011 we formed a consortium for prostate SBRT with a two-
fold purpose: ﬁrst, to analyze all of the currently available clinical
data and second, to establish a centralized center for prospective
data acquisition and analysis accessible to all current and future
eligible centers. At present only a handful of smaller studies using
SBRT for prostate cancer have been published which have shown
successful outcomes with low toxicity proﬁles [11–18]. The merits
of the current study are to pool all of the available published, as
well as unpublished data, into a sufﬁciently large dataset to pro-
vide benchmark conclusions regarding overall effectiveness and
to also allow for hypothesis-testing with regard to the impact of
risk-groups, total dose, or concurrent use of ADT. Given its size
and follow-up it also serves as a more convincing basis for compar-
ison with other approaches for the deﬁnitive treatment of prostate
cancer.
In this report we present the consortium data collected thus far
and the clinical outcomes. Nearly half of the patients reported
herein represent new data, having either not been included in prior
studies or who now have updated follow-up. Early and late toxicity
data acquisition and analysis is ongoing and will be reported
separately.Methods and materials
Study design
A separate IRB was for centralized data collection and analysis
was obtained at this academic institution. In the present study, pa-
tients enrolled in separate IRB-approved prospective phase II clin-
ical trials of prostate SBRT from 8 centers were pooled, yielding a
total of 1100 patients treated between years 2003 and 11. It is
noted that nearly half of the patients reported upon in this study
represent new data not previously published. Eligible patients
had biopsy-proven newly diagnosed, non-metastatic and un-
treated prostate cancer. For each trial the endpoints included early
and late urinary and rectal toxicities, questionnaire-based quality
of life measures and PSA response. Prostate cancer risk stratiﬁca-
tion followed the standard D’Amico risk stratiﬁcation (low risk:
PSA <10 and Gleason sum of 6 and clinical stage T1c–T2a, interme-
diate risk: PSA 10–20 or Gleason sum of 7 or clinical stage T2b, and
high-risk: PSA >20 or Gleason sum 8–10 or clinical stage T2c/T3).
Patient characteristics are summarized in Table 1. Median patient
age was 70 (range 44–91 years old).Treatment speciﬁcs
The CyberKnife (Accuray Inc., Sunnyvale CA) was used to deliver
ﬁducial-based image-guided SBRT. The treatment speciﬁcs from
individual centers have been published previously [11–17]. Differ-
ences among the eight centers are primarily related to dose while
the remainder of the technical treatment speciﬁcations remained
remarkably uniform. The most common general principles are only
brieﬂy outlined here. Three to four gold ﬁducials were placed in the
prostate via trans-rectal ultrasound (some used a trans-perineal
approach), followed by a non-contrast CT scan in the supine posi-
tion and in an alpha cradle. Anatomical contours of the prostate,
seminal vesicles, rectum, bladder, penile bulb, femoral heads and
testes were generated. For homogeneous planning, dose was pre-
scribed to the planning target volume (PTV) that consisted of a vol-
umetric expansion of the prostate by 5 mm, reduced to 3 mm in
the posterior direction. For heterogeneous planning (i.e., HDR-like
dosimetry) the PTV expansion was 2 mm, reduced to 0 mm poste-riorly. The course of radiotherapy consisted of a median of
36.25 Gy (range 35–40 Gy) over 5 fractions (given daily among
>95% of patients, every other day for the remainder). The
overwhelming majority of patients (89%) received a dose of
35–36.25 Gy in 5 fractions. Homogeneous dose planning was used
in >90% of patients (heterogenous HDR-like DVHs were given to
the remainder). For the homogenous planning, dose was normal-
ized to the 90% isodose line in order for the prescription dose to
cover at least 95% of the PTV. Generally speaking, dose volume his-
togram (DVH) goals for the rectum were such that the V50% <50%
(i.e., the volume receiving 50% of the prescribed dose was <50%),
V80% <20%, V90% <10% and V100% <5%. The bladder DVH goals
were V50% <40% and V100% <10%. The femoral head DVH goal
was V40% <5%.
A short course (median 4 months) of neoadjuvant and concur-
rent androgen deprivation therapy (ADT) was allowed at the dis-
cretion of the treating physician and given to 8%, 15% and 38% of
patients within the low-, intermediate- and high-risk groups,
respectively.Follow-up and analysis
In general, PSAs were obtained at baseline, and prospectively at
3 months post-treatment intervals during the ﬁrst 2 years and at
6 month intervals thereafter. The PSA relapse deﬁnition used was
the currently adopted standard of care Phoenix deﬁnition (i.e., na-
dir +2). Biochemical relapse free survival (bRFS or PSA RFS) was
calculated with the Kaplan Meier method and differences between
groups determined by the logrank test. A benign PSA bounce was
called when PSA rose by >0.2 ng/mL above the post-treatment na-
dir and subsequently returned to nadir levels or below.Results
With a median follow-up of 36 months there were 49 patients
with a strictly deﬁned PSA failure (4.5%) 9 of whom were however
determined to be benign PSA bounces since they subsequently fell
to below nadir levels. The 5-year biochemical relapse free survival
(bRFS) rate was 93% for all patients. It was 95%, 83% and 78% for GS
66, 7 and P8, respectively (p = 0.001), and 95%, 84% and 81% for
low-, intermediate- and high-risk patients, respectively
(p < 0.001) (Fig. 1). The 5-year bRFS rates as a function of total dose
or ADT use are summarized in Table 2. No differences in bRFS were
observed as a function of total dose (p = 0.17), or related to the use
of ADT (p = 0.71). Even when substratiﬁed within each individual
risk group, neither the addition of ADT nor the total dose resulted
in signiﬁcant differences in bRFS rates (Table 3).
PSA decline after SBRT gradually fell to an overall median of
0.20 ng/mL at 3-years. While the post-treatment PSA at 3-years
was progressively lower as a function of total dose, with a mean
and median PSA of 0.51 and 0.3 for 35 Gy, 0.35 and 0.20 for
36.25 Gy and 0.29 and 0.20 for 38–40 Gy, this did not translate into
any signiﬁcant differences in bRFS rates as a function of dose (Ta-
ble 2). A PSA bounce of >0.2 ng/ml was noted among 16% of pa-
tients at a median of 36 months, with median bounce height of
0.50 ng/ml (range 0.2–5.29).
There were 135 patients possessing a minimum of 5 years fol-
low-up (range 60–72 months) 77% of whom were low-risk, 21%
intermediate-risk and only 2% high-risk. The 5-year bRFS was
97% for this entire cohort, 99% for patients with low-risk and 93%
for patients with intermediate-risk (p = 0.11). Neither the total
dose nor the use of ADT was signiﬁcantly associated with bRFS.
Although not signiﬁcant, the 5-year bRFS was 93% for patients
receiving a dose 35 Gy vs. 100% for those receiving P36.25 Gy.
Table 1
Patient and treatment characteristics (n = 1100).
Risk group N (%) 35 Gy 36.25 Gy 38–40 Gy ADT use FU*
Low 641 (58%) 254 (40%) 319 (50%) 68 (11%) 50 (8%) 36
Intermediate 334 (30%) 108 (32%) 188 (56%) 38 (11%) 49 (15%) 30.5
High 125 (11%) 23 (18%) 82 (66%) 20 (16%) 48 (38%) 23
Total 1100 385 (35%) 589 (54%) 126 (11%) 147 (14%)
Participating institutions:
Flushing Radiation Oncology, Flushing, NY.
Naples Radiation Oncology, Naples, FL.
Dept. of Radiation Oncology, Beth Israel Deaconness, Boston, MA.
Radiosurgery Medical Group, San Diego, CA.
Division of Radiation Oncology, San Bortolo Hospital, Vicenza, Italy.
Dept. of Radiation Oncology, Stanford, CA.
Dept. of Radiation Oncology, Georgetown University, Washington DC.
Dept. of Radiation Oncology, Swedish Medical Center, Seattle, WA.
 % calculated with respect to the total number of patients within each respective risk-group.
* Median follow-up in months.










Paent number at risk 
PSA Relapse-Free Survival at 5 years 
Low Risk  95% - 
Intermediate Risk 84% p=0.03 
High Risk  81% p<0.0001 
Fig. 1. PSA relapse-free survival Kaplan–Meier curves stratiﬁed by risk group. The
5-year actuarial PSA relapse-free survival rates are 95%, 84% and 81% for low-,
intermediate- and high-risk patients, respectively (p < 0.0001). Censoring is indi-
cated by tick marks on the curves and the number of patients at risk is given for the
time intervals indicated.
Table 2
5-year Kaplan–Meier PSA relapse-free survival rates as a function of risk group, use of
ADT and dose.
5-yr bRFS p-Value
Low Risk 95.2% *
Intermediate Risk 84.1% p = 0.03
High Risk 81.2% p < 0.0001
ADT use 92.6% *
No ADT 91.3% p = 0.71
Dose 35 Gy 92.5% *
Dose 36.25 Gy 90.7% p = 0.08
Dose 38–40 G y 95.8% p = 0.83
* Reference group.
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This consortium project has demonstrated the feasibility of a
centralized multi-institutional data collection and analysis of
prospective clinical trials for prostate SBRT. Data thus far accumu-
lated on 1100 patients from eight independent centers allow for
the reporting of the long term clinical outcomes as well as testing
the effect of ADT with SBRT and the effect of total dose. The three
principal conclusions were: (1) the overall long term bRFS were
excellent, 93% for all patients, and 95%, 84% and 81% for low-,intermediate- and high-risk patients, respectively (p < 0.001); (2)
no differences in bRFS were observed with or without the use of
ADT (p = 0.71); and (3) no differences were observed as a function
of total dose (p = 0.17).
A comparison between all deﬁnitive therapies for localized
prostate cancer (i.e., radical prostatectomy, conventional external
beam radiotherapy, permanent low dose-rate brachytherapy, and
high dose-rate brachytherapy) is well beyond the possible scope
of this study. However, as a surrogate for any such necessary com-
parison, we chose a validated nomogram [20] that in essence com-
prises a synthesis of all modern surgical and radiotherapy outcome
studies. Using patient characteristics as upper and lower bounds
based on the D’Amico risk groups we calculate using the nomo-
gram the following 5-year range in predicted biochemical RFS rates
after radical prostatectomy as 95–98%, after 78 Gy external beam
radiotherapy as 91–94%, and after permanent brachytherapy as
80–90%. Nomograms are of course susceptible to all of the caveats
of retrospective studies, therefore we consider outcomes of >90%
among all of the therapeutic options for low-risk prostate cancer
to be essentially equivalent. Similar conclusions are drawn from
such comparisons within the intermediate- and high-risk groups.
We note however that while our data for the high-risk group is
very encouraging, given the relatively low number of patients
and shorter follow-up available, that one should remain cautious
at the present time. There are two notable multi-institutional ran-
domized clinical trials that have recently opened comparing SBRT
to conventionally fractionated IMRT: the PACE trial (Prostate Ad-
vances in Comparative Evidence) will examine outcomes between
radical prostatectomy, IMRT (78 Gy in 39 fractions) or CyberKnife
SBRT (36.25 Gy in 5 fractions or 38 Gy in 4 fractions) for low and
intermediate risk prostate cancer, and the other a Swedish trial
HYPO-RT-PC (Hypofractionated radiotherapy of intermediate risk
localized prostate cancer) will compare 78 Gy in 39 fractions with
IMRT vs. SBRT 42.7 Gy in 7 fractions of 6.1 Gy.
It is interesting to note that our data did not reveal a dose re-
sponse for SBRT within the range of 35–40 Gy with respect to bRFS
rates. This is not altogether surprising when one considers that
these extreme hypofractionated doses likely correspond biologi-
cally to 90 Gy or higher at conventional fractionation (i.e., 1.8–
2 Gy per fraction) if our radiobiological assumption of prostate
cancer is correct. These high doses are considered to lie near the
plateau of the known sigmoidal dose–response for prostate cancer
where the 5-year bRFS rates lie above the 90% level. Given this
observation, we feel further escalation of SBRT doses above 40 Gy
is not warranted at this time and would not be prudent given the
potential for higher rates of grade 3 GI and GU toxicities shown
for SBRT to 50 Gy [18]. Higher doses could hypothetically be
necessary for SBRT among patients with high-risk localized
Table 3
Comparisons of 5-year PSA relapse-free survival rates by risk group and substratiﬁed by use of ADT or total dose.
Low risk Intermediate risk High risk
5-yr bRFS p-Value 5-yr bRFS p-Value 5-yr bRFS p-Value
ADT use 96.8% * 97.2% * 82.5% *
No ADT 95.1% 0.46 79.7% 0.17 80.2% 0.50
Dose 35 Gy 95.8% * 72.3% * NE *
Dose 36.25 Gy 95.0% 0.77 87.2% 0.73 74.1% 0.99
Dose 38–40 Gy 94.4% 0.41 96.7% 0.58 NE 1.0
NE, no events.
* Reference group.
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lent bRFS rates with SBRT are further support of the consistent
radiobiological picture of prostate cancer as being inherently highly
sensitive to large dose per fraction.
Our data did not reveal any beneﬁt for a short-course of ADT
when given with SBRT, even within the intermediate- and high-
risk groups. We suspect that this is a consequence of the high bio-
logical doses that SBRT corresponds to. The evidence for improved
outcomes with the addition of ADT originates from clinical trials
where the external beam dose was 70 Gy. Indeed, there is current
retrospective evidence that with conventionally fractionated dose-
escalation to 78 Gy or higher there may be little to gain from ADT.
However, only a randomized trial will be able to settle this
question.
When considering toxicities, it is challenging to separate differ-
ences resulting from technique alone, i.e., 3D vs. IMRT vs. IGRT,
from that of dose-escalation itself. Caution should therefore be
made when comparing SBRT, which inherently adopts rather small
PTV margins and provides intra-fraction IGRT, to dose-escalation
IMRT. Data comparing the early and late GI and GU toxicities of
moderately hypofractionated dose regimens have been reported
among randomized trials and have shown no signiﬁcant differ-
ences when compared to conventionally fractionated dose-esca-
lated courses [2–10]. So far, data from published prostate SBRT
trials have shown late grade 3 GI and GU toxicities within the 1–
3% range [11–17] with the exception of one SBRT trial giving
50 Gy in 5 fractions resulting in a 7% grade 3 toxicity for both late
GI and GU [18]. The toxicity counterpart of this consortium data
will be presented separately [21]. That study examined patients
with a median follow-up of 3 years and evaluable patients out to
more than 5 years using patient self-reported QOL using the EPIC
validated tool (expanded prostate cancer index composite). A tran-
sient decline in the urinary and bowel domains was observed with-
in the ﬁrst 3 months after SBRT which returned to baseline status
or better within 6 months and remained so beyond 5 years. The
same pattern was observed among patients with good vs. poor
baseline function and was independent of the degree of early
toxicities.Conclusion
PSA relapse-free survival rates after SBRT compare very favor-
ably with other deﬁnitive treatments for low and intermediate risk
groups. The data for high risk patients is very encouraging but re-
quires longer follow-up at this time. The added beneﬁt of ADT for
any risk group has not yet been demonstrated. A dose–response
within the range of 35–40 Gy in 5 fractions has not been observed
and therefore escalation beyond 40 Gy is not warranted at this
time, especially for low- and intermediate-risk patients. The cur-
rent evidence supports consideration of SBRT among the deﬁnitivetherapeutic options for localized prostate cancer with low and
intermediate risk.Conﬂict of interest
Several physicians have received speaker honoraria for presen-
tations at conferences, otherwise none of the authors have any
conﬂict of interest regarding the content, treatment, drugs or tech-
nology associated with this report.References
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